• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

WBP2 通过与 LATS1 竞争结合 WWC3 负调控 Hippo 通路,促进非小细胞肺癌进展。

WBP2 negatively regulates the Hippo pathway by competitively binding to WWC3 with LATS1 to promote non-small cell lung cancer progression.

机构信息

Department of Pathology, College of Basic Medical Sciences and the First Affiliated Hospital of China Medical University, Shenyang, China.

Department of Pathology, the First Affiliated Hospital of China Medical University, Shenyang, China.

出版信息

Cell Death Dis. 2021 Apr 9;12(4):384. doi: 10.1038/s41419-021-03600-3.

DOI:10.1038/s41419-021-03600-3
PMID:33837178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8035140/
Abstract

WW domain binding protein-2 (WBP2) can function as a Yes-associated protein/transcriptional co-activator with PDZ-binding motif (YAP/TAZ) co-activator and has a crucial role in promoting breast cancer progression. However, the expression and potential molecular mechanisms of WBP2 in the context of lung cancer are not fully understood. We determined that WBP2 was highly expressed in lung cancer specimens and cell lines and that this expression was closely related to the advanced pTNM stage, lymph node metastasis, and poor prognosis of patients. In addition, gain- and loss-of-function experiments revealed that WBP2 could significantly promote the proliferation and invasion of lung cancer cells both in vivo and in vitro. To elucidate the underlying molecular mechanism, we determined that wild-type WBP2 could competitively bind to the WW domain of WWC3 (WW and C2 domain-containing-3) with LATS1 (Large tumor suppressor-1) through its PPxY motifs, thus inhibiting the formation of the WWC3-LATS1 complex, reducing the phosphorylation level of LATS1, suppressing the activity of the Hippo pathway, and ultimately promoting YAP nuclear translocation. Therefore, from the aspect of upstream molecules of Hippo signaling, WBP2 promotes the malignant phenotype of lung cancer cells in a unique manner that is not directly dependent upon YAP, thus providing a corresponding experimental basis for the development of targeted therapeutic drugs for lung cancer.

摘要

WW 结构域结合蛋白-2(WBP2)可以作为 PDZ 结合基序(YAP/TAZ)共激活子的 Yes 相关蛋白/转录共激活子发挥作用,在促进乳腺癌进展方面发挥着关键作用。然而,WBP2 在肺癌中的表达和潜在分子机制尚不完全清楚。我们确定 WBP2 在肺癌标本和细胞系中高表达,并且这种表达与晚期 pTNM 分期、淋巴结转移和患者预后不良密切相关。此外,增益和缺失功能实验表明,WBP2 可以显著促进肺癌细胞在体内和体外的增殖和侵袭。为了阐明潜在的分子机制,我们确定野生型 WBP2 可以通过其 PPxY 基序与 LATS1(大肿瘤抑制因子-1)竞争性结合 WWC3(WW 和 C2 结构域包含 3)的 WW 结构域,从而抑制 WWC3-LATS1 复合物的形成,降低 LATS1 的磷酸化水平,抑制 Hippo 信号通路的活性,并最终促进 YAP 核易位。因此,从 Hippo 信号通路的上游分子来看,WBP2 以一种不直接依赖于 YAP 的独特方式促进肺癌细胞的恶性表型,从而为开发针对肺癌的靶向治疗药物提供了相应的实验基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/2a221d1da545/41419_2021_3600_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/7606cf7d46af/41419_2021_3600_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/8946035bed32/41419_2021_3600_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/d265ddb085ea/41419_2021_3600_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/9a75c75a790c/41419_2021_3600_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/2c7f87f43460/41419_2021_3600_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/2a221d1da545/41419_2021_3600_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/7606cf7d46af/41419_2021_3600_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/8946035bed32/41419_2021_3600_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/d265ddb085ea/41419_2021_3600_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/9a75c75a790c/41419_2021_3600_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/2c7f87f43460/41419_2021_3600_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76ed/8035140/2a221d1da545/41419_2021_3600_Fig6_HTML.jpg

相似文献

1
WBP2 negatively regulates the Hippo pathway by competitively binding to WWC3 with LATS1 to promote non-small cell lung cancer progression.WBP2 通过与 LATS1 竞争结合 WWC3 负调控 Hippo 通路,促进非小细胞肺癌进展。
Cell Death Dis. 2021 Apr 9;12(4):384. doi: 10.1038/s41419-021-03600-3.
2
WWC3 regulates the Wnt and Hippo pathways via Dishevelled proteins and large tumour suppressor 1, to suppress lung cancer invasion and metastasis.WWC3 通过 Dishevelled 蛋白和大肿瘤抑制因子 1 调节 Wnt 和 Hippo 通路,抑制肺癌的侵袭和转移。
J Pathol. 2017 Aug;242(4):435-447. doi: 10.1002/path.4919. Epub 2017 Jun 29.
3
WW domain-mediated interaction with Wbp2 is important for the oncogenic property of TAZ.WW 结构域与 Wbp2 的相互作用对于 TAZ 的致癌特性很重要。
Oncogene. 2011 Feb 3;30(5):600-10. doi: 10.1038/onc.2010.438. Epub 2010 Oct 25.
4
WWC3 inhibits intimal proliferation following vascular injury via the Hippo signaling pathway.WWC3 通过 Hippo 信号通路抑制血管损伤后的内膜增殖。
Mol Med Rep. 2018 Apr;17(4):5175-5183. doi: 10.3892/mmr.2018.8484. Epub 2018 Jan 25.
5
FRMPD1 activates the Hippo pathway via interaction with WWC3 to suppress the proliferation and invasiveness of lung cancer cells.FRMPD1通过与WWC3相互作用激活Hippo信号通路,以抑制肺癌细胞的增殖和侵袭。
Cancer Manag Res. 2019 Apr 18;11:3395-3410. doi: 10.2147/CMAR.S194512. eCollection 2019.
6
WBP2 promotes gastric cancer cell migration via novel targeting of LATS2 kinase in the Hippo tumor suppressor pathway.WBP2 通过 Hippo 肿瘤抑制通路中 LATS2 激酶的新靶向作用促进胃癌细胞迁移。
FASEB J. 2021 Feb;35(2):e21290. doi: 10.1096/fj.202000393R.
7
Reciprocal Regulation of Hippo and WBP2 Signalling-Implications in Cancer Therapy.Hippo 和 WBP2 信号的相互调节——在癌症治疗中的意义。
Cells. 2021 Nov 11;10(11):3130. doi: 10.3390/cells10113130.
8
Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.Hippo 通路与小分子 GTP 酶通路对 YAP/TAZ 的相互调控。
Small GTPases. 2020 Jul;11(4):280-288. doi: 10.1080/21541248.2018.1435986. Epub 2018 Apr 20.
9
Hippo/MST blocks breast cancer by downregulating WBP2 oncogene expression via miRNA processor Dicer.Hippo/MST 通过 miRNA 处理器 Dicer 下调 WBP2 癌基因表达来抑制乳腺癌。
Cell Death Dis. 2020 Aug 21;11(8):669. doi: 10.1038/s41419-020-02901-3.
10
Identification of zinc finger MIZ-type containing 2 as an oncoprotein enhancing NAD-dependent protein deacetylase sirtuin-1 deacetylase activity to regulate Wnt and Hippo pathways in non-small-cell lung cancer.鉴定锌指 MIZ 型蛋白 2 作为一种癌蛋白,可增强 NAD 依赖性蛋白去乙酰化酶 Sirtuin-1 的去乙酰化酶活性,从而调节非小细胞肺癌中的 Wnt 和 Hippo 通路。
Cell Mol Biol Lett. 2024 Sep 12;29(1):122. doi: 10.1186/s11658-024-00636-z.

引用本文的文献

1
The components and regulation of the Hippo pathway and its relationships with the progression and treatment of Non-small cell lung cancer (NSCLC).Hippo信号通路的组成、调控及其与非小细胞肺癌(NSCLC)进展和治疗的关系。
Cancer Cell Int. 2025 Aug 20;25(1):309. doi: 10.1186/s12935-025-03946-0.
2
SIRT1 silencing ameliorates malignancy of non-small cell lung cancer via activating FOXO1.沉默 SIRT1 通过激活 FOXO1 改善非小细胞肺癌的恶性程度。
Sci Rep. 2024 Aug 28;14(1):19948. doi: 10.1038/s41598-024-70970-x.
3
TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.

本文引用的文献

1
Hippo/MST blocks breast cancer by downregulating WBP2 oncogene expression via miRNA processor Dicer.Hippo/MST 通过 miRNA 处理器 Dicer 下调 WBP2 癌基因表达来抑制乳腺癌。
Cell Death Dis. 2020 Aug 21;11(8):669. doi: 10.1038/s41419-020-02901-3.
2
miR-21-5p promotes lung adenocarcinoma cell proliferation, migration and invasion via targeting WWC2.miR-21-5p 通过靶向 WWC2 促进肺腺癌细胞的增殖、迁移和侵袭。
Cancer Biomark. 2020;28(4):549-559. doi: 10.3233/CBM-201489.
3
Itch attenuates CD4 T-cell proliferation in mice by limiting WBP2 protein stability.
TMEM120B 通过与 MYH9 结合,增强乳腺癌细胞干性并通过 β1 整合素/FAK-TAZ-mTOR 信号轴加速化疗耐药性。
Breast Cancer Res. 2024 Mar 19;26(1):48. doi: 10.1186/s13058-024-01802-z.
4
ZNF500 abolishes breast cancer proliferation and sensitizes chemotherapy by stabilizing P53 via competing with MDM2.ZNF500 通过与 MDM2 竞争稳定 P53,从而消除乳腺癌增殖并通过化疗增敏。
Cancer Sci. 2023 Nov;114(11):4237-4251. doi: 10.1111/cas.15947. Epub 2023 Sep 12.
5
WW domain binding protein 2 (WBP2) as an oncogene in breast cancer: mechanisms and therapeutic prospects-a narrative review.WW结构域结合蛋白2(WBP2)作为乳腺癌中的一种癌基因:作用机制与治疗前景——一篇叙述性综述
Gland Surg. 2022 Dec;11(12):1984-2002. doi: 10.21037/gs-22-716.
6
Reciprocal Regulation of Hippo and WBP2 Signalling-Implications in Cancer Therapy.Hippo 和 WBP2 信号的相互调节——在癌症治疗中的意义。
Cells. 2021 Nov 11;10(11):3130. doi: 10.3390/cells10113130.
7
WBP2 promotes BTRC mRNA stability to drive migration and invasion in triple-negative breast cancer via NF-κB activation.WBP2 通过激活 NF-κB 促进三阴性乳腺癌中 BTRC mRNA 的稳定性,从而推动迁移和侵袭。
Mol Oncol. 2022 Jan;16(2):422-446. doi: 10.1002/1878-0261.13048. Epub 2021 Aug 12.
瘙痒通过限制 WBP2 蛋白稳定性来减弱小鼠 CD4 T 细胞的增殖。
Eur J Immunol. 2020 Oct;50(10):1468-1483. doi: 10.1002/eji.201948323. Epub 2020 Jun 9.
4
Expression of large tumour suppressor (LATS) kinases modulates chemotherapy response in advanced non-small cell lung cancer.大肿瘤抑制激酶(LATS)的表达调节晚期非小细胞肺癌的化疗反应。
Transl Lung Cancer Res. 2020 Apr;9(2):294-305. doi: 10.21037/tlcr.2020.03.26.
5
The emerging roles of WBP2 oncogene in human cancers.WBP2 致癌基因在人类癌症中的新兴作用。
Oncogene. 2020 Jun;39(24):4621-4635. doi: 10.1038/s41388-020-1318-0. Epub 2020 May 11.
6
Low LATS2 expression is associated with poor prognosis in non-small cell lung carcinoma.低LATS2表达与非小细胞肺癌的不良预后相关。
Pol J Pathol. 2019;70(3):189-197. doi: 10.5114/pjp.2019.90395.
7
microRNA-485-5p inhibits the progression of hepatocellular carcinoma through blocking the WBP2/Wnt signaling pathway.miRNA-485-5p 通过阻断 WBP2/Wnt 信号通路抑制肝癌的进展。
Cell Signal. 2020 Feb;66:109466. doi: 10.1016/j.cellsig.2019.109466. Epub 2019 Nov 6.
8
Elevated WBP2 Expression in HER2-positive Breast Cancers Correlates with Sensitivity to Trastuzumab-based Neoadjuvant Therapy: A Retrospective and Multicentric Study.HER2 阳性乳腺癌中 WBP2 表达升高与曲妥珠单抗为基础的新辅助治疗敏感性相关:一项回顾性和多中心研究。
Clin Cancer Res. 2019 Apr 15;25(8):2588-2600. doi: 10.1158/1078-0432.CCR-18-3228. Epub 2018 Dec 28.
9
The Hippo Pathway: Biology and Pathophysiology.Hippo 通路:生物学与病理生理学。
Annu Rev Biochem. 2019 Jun 20;88:577-604. doi: 10.1146/annurev-biochem-013118-111829. Epub 2019 Dec 19.
10
The transcriptional coactivator WBP2 primes triple-negative breast cancer cells for responses to Wnt signaling via the JNK/Jun kinase pathway.转录共激活因子 WBP2 通过 JNK/Jun 激酶通路为三阴性乳腺癌细胞对 Wnt 信号的反应做好准备。
J Biol Chem. 2018 Dec 28;293(52):20014-20028. doi: 10.1074/jbc.RA118.005796. Epub 2018 Nov 15.